In this article, we will look at the 10 Best Affordable Healthcare Stocks to Buy Now.
On December 26, Bernstein analyst Lance Wilkes appeared on CNBC to talk about the outlook for the managed care providers in 2026, along with how the rising healthcare costs could be best addressed.
According to him, this has been a year where certain areas of healthcare, particularly those related to health spend or real significant turnarounds in business, have performed pretty well, allowing certain companies in the domain from benefit from the trends. In addition, the broad space is experiencing a stabilization in some of the health insurers. They have been going through a “super cycle”, according to Wilkes, which has impacted them in terms of pricing, especially related to the government programs, with trends of stability exhibited by the second half of the year.
READ ALSO: 12 Most Widely Held Stocks by Hedge Funds in 2025 and 12 Small Cap Stocks to Buy with Huge Upside Potential.
Discussing the potential implications for investors and how it could impact the stock price if there is an attempt for managed care organizations to tackle the costs of medicines, Wilkes noted that there are several opportunities, as this particular domain constitutes a very small subset of the overall health insurance market. The more important aspect that investors should be looking at, according to him, is this traditonal insurance cycle, which is essentially a super cycle, according to him. He added that we are seeing a withdrawal of competition and capital, which is going to lead to a firming of prices and improvements in margin.
With these trends in view, let’s look at the best affordable healthcare stocks to buy now.
Our Methodology
We used stock screeners to make a list of healthcare stocks with a forward P/E below 15 and selected the top 10 stocks with the highest number of hedge fund holders, as of Q3 2025. We sourced the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of hedge fund holders.
Note: All data was recorded on December 26.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
10 Best Affordable Healthcare Stocks to Buy Now
10. Sanofi (NASDAQ:SNY)
Forward P/E: 10.63
Number of Hedge Fund Holders: 32
Sanofi (NASDAQ:SNY) is one of the best affordable healthcare stocks to buy now. Sanofi (NASDAQ:SNY) announced on December 24 an agreement to acquire Dynavax Technologies Corporation, which is a publicly traded vaccines company with a marketed adult hepatitis B vaccine (HEPLISAV-B®) and a differentiated shingles vaccine candidate. Dynavax’s adult hepatitis B vaccine HEPLISAV-B is marketed in the United States, and holds a differentiated position due to its its two-dose regimen over one month compared to other hepatitis B vaccines, which are administered in three doses over six months.
In another development, Berenberg Bank analyst Luisa Hector reaffirmed a Buy rating on Sanofi (NASDAQ:SNY) on December 19 and set a price target of €105.00.
The same day, Sanofi (NASDAQ:SNY) announced an agreement with the Donald Trump administration to ensure increased access to affordable medications granted to American patients while simultaneously supporting the country’s role in biopharmaceutical manufacturing and innovation. The agreement entails Sanofi (NASDAQ:SNY) confirming its growth strategy to support its role as a driver of progress and positive impact by taking the lead through “breakthrough science”.
Management reported that the confidential and voluntary agreement between President Trump’s administration and the company satisfies all four requests outlined in the President’s July 31, 2025, letter, and would ensure that certain Sanofi (NASDAQ:SNY) medications can be accessed by state Medicaid programs at the same prices available to other high-income nations. The agreement would thus slash prices by an average of 61% for particular medications targeting cardiovascular and neurological conditions, diabetes, and cancer. Sanofi (NASDAQ:SNY) added that it would also provide consumers access to lower-cost medicines via the TrumpRx.gov and other direct-to-patient platforms, offering nearly 70% of average savings on particular medicines that treat diabetic and cardiovascular conditions.
Sanofi (NASDAQ:SNY) researches, produces, and distributes pharmaceutical products. The company’s operations are divided into the Pharmaceuticals, Consumer Healthcare, and Vaccines segments.
9. GSK plc (NYSE:GSK)
Forward P/E: 11.48
Number of Hedge Fund Holders: 41
GSK plc (NYSE:GSK) is one of the best affordable healthcare stocks to buy now. GSK plc (NYSE:GSK) announced on December 19 an agreement with the United States administration to lower the cost of prescription medications for patients in the US, which includes the company’s broad respiratory portfolio targeting the treatment of over 40 million Americans suffering from respiratory conditions such as COPD and asthma.
The agreement entails GSK plc (NYSE:GSK) lowering the price of certain medicines in Medicaid, along with launching new products with a higher balance pricing approach that recognises the value of innovation across developed nations. Management reported that the agreement satisfies all four actions requested by President Trump in his July 31st letter.
GSK plc (NYSE:GSK) added that it would also “make most” of its inhaled respiratory portfolio, along with other products available to patients, on a direct purchasing platform offering up to 66% of savings. In addition, management reported that as part of the President’s Strategic Active Pharmaceutical Ingredients Reserve (SAPIR), the company would support the resilience of the US supply chain for critical medicines through securing a reserve of albuterol (also known as salbutamol) for the US. Albuterol is the active ingredient in several inhalers that relieve symptoms of COPD and asthma.
While the agreement’s detailed terms remain confidential, management added that the entered agreements covers both GSK plc (NYSE:GSK) and ViiV Healthcare and exclude the two from s232 tariffs for 3 years.
Formerly known as GlaxoSmithKline, GSK plc (NYSE:GSK) is a global biopharma company that develops and distributes a range of vaccines, medications, and consumer health items. It is based in the United Kingdom and has over 20 vaccines in its portfolio. The company also develops cancer treatments for multiple myeloma, ovarian cancer, and endometrial cancer, among others.
